August 13, 2022, Revolution Cancer International Molecular Tumor Board (KRAS dismantled, NSCLC)

In the August 13, 2022, the audience was treated to the PREMIER KRAS bench to bedside, and pipeline to patient discussion on the planet. The MOST UP TO DATE KRAS DATA WAS PRESENTED, including all related August 2022 World Lung Conference data. The Revolution Medicines pipeline was highlighted, as their multi-KRAS, SHP2, and KRAS G12C inhibitors were presented.
In a truly unprecedented fashion, KRAS inhibitor drug development considerations and concerns were detailed in the context of two stage 4 non-small cell lung cancer patients.
Thereafter, an incredible analysis of the stage 4 KRAS G12C mutated non-small cell lung cancer (NSCLC) patients was performed in the context of the COMET algorithm and treatment cartography. All presently FDA-approved non-small cell lung cancer treatments were discussed, including the data that led to their approval. Clinical trials in the stage 4 non-small cell lung cancer space, particularly those involving KRAS G12C, and a treatment map for the aforementioned stage 4 NSCLC patients were depicted. Unmet needs in non-small lung cancer were emphasized, and the RCIMTB team presented new clinical trials to consider.
If that wasn't enough the RCIMTB took it up another level to discuss KRAS G12D, including the June 2022 NEJM paper depicting KRAS G12D CAR-T therapy. Novel pancreatic cancer clinical trials were postulated.
Taking it up even more the RCIMTB team discussed KRAS G13C and KRAS Q61H mutations.
NOBODY HAS DONE WHAT WAS DONE IN THIS TUMOR BOARD OR THE TWO PRIOR RCIMTB TUMOR BOARDS. MSK, MD Anderson, Johns Hopkins, Mayo, etc., are not doing what is being done here, but they should be.
If you don't believe that, PLEASE SEE FOR YOURSELF.
This tumor board was hosted by:
Basem S. Goueli MD, PhD, MBA (co-host): CEO and Founder of CancerLight, Cancer Clarity, and Revolution Cancer Medical Care PLLC, medical director for 2 Xbiotech trials, full-time GENERAL hematologist/oncologist, consultant for numerous companies, writer of "The Insider's Guide to Translational Medicine" on biopharmatrend.com and "The Cancer Patients Don't Have an Expiration Date Series" on revolutioncancer.com, author and speaker of the "If You Were My Family Member" cancer patient education series on revolutioncancer.com and this channel
Janakiraman Subramanian MD (co-host): Co-Director of Thoracic Oncology at Inova Schar Cancer Institute (ISCI), and Director for ISCI Data and Analytics Research Core.
Silambarasan Maskomani Ph.D. (co-host): Personalized healthcare ecosystem partner for Roche, where he is currently helping build a precision oncology program in India.
It featured:
Bhadresh Rami Ph.D.: Senior Consultant and Advisor for Smagen, 15 years of drug development experience.
Ali Ucar: CEO and co-founder of CaresolutionsUSA

[@dhruvsxu]

Well done guys!

[@revolutioncancer6610]

We need you to be a cohost with us Dhruv.